All News

psA.fil_.Hands_.jpg

Novel and Emerging Therapies in Psoriatic Arthritis

Antoni Chan, MD, PhD

Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.

Read Article
guidelines.recommendations.jpg

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

Michael Putman, MD, MSCI

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.

Read Article
Prgnancy,outcome

Improving fertility in women with RA

Jiha Lee, MD

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.

Read Article
Playing it Safe with RA? JAK vs. TNF Debate The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX
Dr. John Cush RheumNow ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib Dr. Richard Conway discusses abstract 0770, presented at #ACR24 https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe

Links:

Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024! View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs. https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush RheumNow ( View Tweet)
ANCA Vasculitis "Eye": Can rituximab help? Dr. Janet Pope discusses abstract 0726 at #ACR24 https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P

Links:

Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

Links:

Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq

Links:

Dr. John Cush RheumNow ( View Tweet)
Time the💉 Response to pneumococcal vaccine better when given before starting MTX. Stay updated on ACR and EULAR vaccination recommendations! #ACR24 @RheumNow ABST#2676

Jiha Lee JihaRheum ( View Tweet)

#Ianalumab 300 mg sc q monthly B cell depleted and changes BAFF signalling 👇⬇️IFN May be promising in #lupus #SLE +data in primary #Sjogrens ACR24 @RheumNow @ACRheum Abst#2425 Needs Phase3 ➡️I suspect safer than CAR T and Bispecific T cell engagers but ? ⬇️efficacy

Janet Pope Janetbirdope ( View Tweet)

Prof Petri reports the ff predictors of fracture in SLE: -older age -Caucasian race -female sex ⚠️ Prednisone (but not recent IM triamcinolone or IV methylpred) is a MAJOR risk factor. When possible, avoid prednisone! @RheumNow #ACR24 #ACRbest abs2679 @rheumarhyme https://t.co/q2NMRaYsAF

Links:

sheila RHEUMarampa ( View Tweet)
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld

Links:

Richard Conway RichardPAConway ( View Tweet)
All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆 I keep saying this; our obsesssion with vitamin d is not commensurate w/reality It's. The. Prednisone. #ACR24 @RheumNow Abstr#2679 #ACRBest https://t.co/13luByNvYT

Links:

Mike Putman EBRheum ( View Tweet)
Does CVD mortality risk change after stopping GC in RA? ➡️28078 incident GC users ➡️Incr mortality risk from CVD &infections persists post-cessation ➡️Risk never returns to pre-GC level after prolonged use ⏩Use GC at lowest dose for shortest time possible Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship #ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf

Links:

Jiha Lee JihaRheum ( View Tweet)
Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1

Links:

Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×